Canine Flu Therapeutics Market Analysis by Antibiotics, Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), and Antiviral Drugs
Rising Pet Humanization, Higher Penetration of Dog Flu around the World, Advent of New Dog Healthcare Research and Treatment Facilities are Propelling the Market Performance. FMI Taps the Data
Canine Flu Therapeutics Market Outlook (2023 to 2033)
The canine flu therapeutics market is anticipated to flourish at an average CAGR of 4.1% between 2023 and 2033. The market is expected to hold a market share of US$ 3.06 billion by 2033, while the market is likely to reach a value of US$ 2.04 billion in 2023.
Canine flu is segmented into two types, they are H3N8 viruses and H3N2 (Seasonal influenza A) viruses.
Attributes
Details
Canine Flu Therapeutics Market CAGR (2023 to 2033)
4.1%
Canine Flu Therapeutics Market Size (2023)
US$ 2.04 billion
Canine Flu Therapeutics Market Size (2033)
US$ 3.06 billion
Almost all dogs are susceptible to canine flu with direct contact or with respiratory discharges from infected dogs. The symptoms of illness are eye discharges, upper respiratory illness, reduced appetite, runny nose, cough, fever, and lethargy.
Moreover, the severity of canine flu ranges from no symptoms to terminal illness, resulting in pneumonia and sometimes death. Therefore, the canine flu therapeutics market is likely to have significant growth during the forecast period and more adoption by dog owners to reduce the spread of flu and infections.
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
Demand Drivers Affecting the Growth of the Canine Flu Therapeutics Market
Several factors have been identified by the experts of FMI while analyzing the canine flu therapeutics in depth that are propelling the market growth at a moderate pace. They are as follows:
Attribute
Details
Rising Diseases
A robust increase in the incidences of diseases with no specific treatment is likely to boost the canine flu therapeutics market expansion.
Innovation
The innovators in the market are getting the advantage of a monopolistic market as there is less competition across the globe.
Government Support
Increasing government support and rising research and development activities by manufacturers are likely to foster the growth of the canine flu therapeutics market in the coming years.
Cost-effectiveness
Rapid turnaround time and lower procedure cost than conventional methods fuel the demand for canine flu therapeutics in the canine influenza treatment market.
Factors Deterring the Market Expansion of Canine Flue Therapeutics
Although key demand drivers have been identified in the canine flu therapeutics market, it is also witnessed that certain aspects are likely to hinder growth and further slow down the pace of expansion for the concerned market. The curbing factors are as follows.
Attribute
Details
Lack of expertise
Lack of awareness and absence of trained professionals in developing and underdeveloped economies may impede the propulsion of the canine flu therapeutics market.
Vaccine Limitations
The global market for canine flu therapeutics is expected to be deterred by a limited number of vaccines available.
Find your sweet spots for generating winning opportunities in this market.
Country-wise Insights
Countries
Revenue Share % (2022)
United States
34.6%
Germany
5.6%
Japan
5.3%
North America
37.6%
Europe
25.3%
Countries
CAGR % (2023 to 2033)
China
4.2%
India
3.4%
United Kingdom
2.4%
Australia
3.0%
How is the North America Canine Flue Therapeutics Market Performing?
North America is projected to hold the highest market share of canine flu therapeutics and is anticipated to dominate the market during the forecast period. The North American region held 37.6% of the market share for canine flu therapeutics in 2022.
The market size in North America is expanding owing to factors like:
Rising infection rates have been recorded in pet dogs in North America.
Increased awareness of the disease and its treatment with diagnostic methods further bolstering the demand for canine flu therapeutics in this region.
Growth Outlook of Europe Canine Flu Therapeutics Market
Europe is anticipated to hold the second-leading share in the global canine flue therapeutics market and has substantial growth over the forecast period. At present, the European region accounts for 25.3% of the total market share of canine flu therapeutics.
The marker size expansion in Europe can be attributed to the following factors:
Increasing animal adoption and rising consumer spending on veterinarian services due to the rise of disposable income in the European regions is driving the growth of the canine flu market.
The technological advancement in the healthcare sector in the region and expanding veterinary healthcare infrastructure are expected to augment the canine flu therapeutics market.
Categorical Analysis
Category
Drug Class
Leading Segment
NSAIDs
Market Share (2022)
57.8%
Category
Distribution Channel
Leading Segment
Veterinary Clinics
Market Share (2022)
44.8%
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need and save 40%!
Start-up Ecosystem
New Entrants Ardently Performing in the Canine Flu Therapeutics Market
According to the research study conducted by FMI, the new entrants in the canine flu therapeutics market continually indulge in several collaborations and highly invest in research and development activities to provide more effective therapeutic solutions to dog owners, which would cure influenza faster and reduce the spread.
Zoetis is a start-up company lining up rival vaccines to fight a new strain of dog flu. The new vaccines don't protect against the previously known strain of dog flu, even though that illness is still circulating. So, dog owners who want total protection must get separate vaccines for H3N8 and H3N2.
Schering-Plough Animal Health is an innovation-driven, science-centered global healthcare company. Schering-Plough creates therapies that help save and improve lives worldwide through biopharmaceutical research and collaborations with partners. The company applies its research-and-development platform to human prescription and consumer products as well as to animal health products and is likely to impact the therapeutics market in the coming years.
Some other start-ups increasing in the market are Wiggles, Fidocure, Itch, Nexvet, Hesterbiosciences, and Gallant.
Competitive Analysis
Market Players to Fuel Further Growth in the Canine Flu Therapeutics Market
The market is highly competitive due to the presence of several participants. The key players are adopting several growth strategies, and finding means to upgrade the vaccines that can cure influenza in animals faster and more cost-effectively.
Recent Developments
In August 2021, Merck Animal Health announced a new name for its cattle vaccine portfolio, one of the industry's prominent and most comprehensive vaccine portfolios. The goal of the new naming and packaging is to make it easier for customers to recognize the company's vaccines and to identify specific formulations.
In November 2020, Merck announced it had received a conditional license from the USDA to market Canine Influenza Vaccine H3N2- just one week after Zoetis received the same USDA nod for its vaccine. Both new vaccines require two doses, administered a few weeks apart.
In October 2018, the European Clinical Office was approved to utilize serological hemagglutination hindrance (HI) for flu testing.
Boehringer Ingelheim International GmbH has decided to expand veterinary vaccine capacity for rising transboundary diseases in France.
Key Players
Interver Inc
Merck Animal Health
al Health
GlaxoSmithKline Plc.
Novartis AG
Bristol-Myers Squibb Company
Eli Lilly and Company
Pfizer Inc.
Boehringer Ingelheim International GmbH
Sanofi
Abbott Laboratories
F. Hoffmann-La Roche Ltd.
Key Segments Covered
By Drug Class:
Antibiotics
Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
Antiviral Drugs
By Distribution Channel:
Veterinary Clinics
Veterinary Pharmacies
Online Pharmacies
Key Regions Covered:
North America
United States
Canada
Latin America
Brazil
Mexico
Rest of Latin America
Europe
Germany
United Kingdom
France
Spain
Russia
Rest of Europe
Japan
Asia Pacific Excluding Japan
China
India
Malaysia
Singapore
Australia
Rest of Asia Pacific Excluding Japan (APEJ)
The Middle East and Africa
GCC Countries
Israel
South Africa
Middle East and Africa (MEA
Frequently Asked Questions
Which countries dominate the global Canine Flu Therapeutics Market?
The United States, Japan, and China dominate the global Canine Flu Therapeutics market.
What is the growth forecast for the Canine Flu Therapeutics market?
The Canine Flu Therapeutics market is forecast to register a CAGR of 4.1% through 2033.
How is the historical performance of the market?
From 2018 to 2022, the market grew at a CAGR of 4%
Which is the top trend in the Canine Flu Therapeutics market?
Technological advancement disrupts the current market trends, such as the development of new vaccines and antiviral drugs.
What is the projected size of the market by 2033?
The global market size of Canine Flu Therapeutics to reach US$ 2.04 billion by 2033.
Table of Content
1. Executive Summarysss
1.1. Global Market Outlook
1.2. Demand-side Trends
1.3. Supply-side Trends
1.4. Technology Roadmap Analysis
1.5. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
3. Market Background
3.1. Market Dynamics
3.1.1. Drivers
3.1.2. Restraints
3.1.3. Opportunity
3.1.4. Trends
3.2. Scenario Forecast
3.2.1. Demand in Optimistic Scenario
3.2.2. Demand in Likely Scenario
3.2.3. Demand in Conservative Scenario
3.3. Opportunity Map Analysis
3.4. Investment Feasibility Matrix
3.5. PESTLE and Porter’s Analysis
3.6. Regulatory Landscape
3.6.1. By Key Regions
3.6.2. By Key Countries
3.7. Regional Parent Market Outlook
4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033
4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022
4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033
4.2.1. Y-o-Y Growth Trend Analysis
4.2.2. Absolute $ Opportunity Analysis
5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Drug Class
5.1. Introduction / Key Findings
5.2. Historical Market Size Value (US$ Million) Analysis By Drug Class, 2018 to 2022
5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Drug Class, 2023 to 2033
5.3.1. Antibiotics
5.3.2. Nonsteroidal anti-inflammatory Drugs (NSAIDs)
5.3.3. Antiviral Drugs
5.4. Y-o-Y Growth Trend Analysis By Drug Class, 2018 to 2022
5.5. Absolute $ Opportunity Analysis By Drug Class, 2023 to 2033
6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Distribution Channel
6.1. Introduction / Key Findings
6.2. Historical Market Size Value (US$ Million) Analysis By Distribution Channel, 2018 to 2022
6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Distribution Channel, 2023 to 2033
6.3.1. Veterinary Clinics
6.3.2. Veterinary Pharmacies
6.3.3. Online Pharmacies
6.4. Y-o-Y Growth Trend Analysis By Distribution Channel, 2018 to 2022
6.5. Absolute $ Opportunity Analysis By Distribution Channel, 2023 to 2033
7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region
7.1. Introduction
7.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022
7.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033
7.3.1. North America
7.3.2. Latin America
7.3.3. Western Europe
7.3.4. Eastern Europe
7.3.5. South Asia and Pacific
7.3.6. East Asia
7.3.7. Middle East and Africa
7.4. Market Attractiveness Analysis By Region
8. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
8.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
8.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
8.2.1. By Country
8.2.1.1. USA
8.2.1.2. Canada
8.2.2. By Drug Class
8.2.3. By Distribution Channel
8.3. Market Attractiveness Analysis
8.3.1. By Country
8.3.2. By Drug Class
8.3.3. By Distribution Channel
8.4. Key Takeaways
9. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
9.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
9.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
9.2.1. By Country
9.2.1.1. Brazil
9.2.1.2. Mexico
9.2.1.3. Rest of Latin America
9.2.2. By Drug Class
9.2.3. By Distribution Channel
9.3. Market Attractiveness Analysis
9.3.1. By Country
9.3.2. By Drug Class
9.3.3. By Distribution Channel
9.4. Key Takeaways
10. Western Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
10.2.1. By Country
10.2.1.1. Germany
10.2.1.2. UK
10.2.1.3. France
10.2.1.4. Spain
10.2.1.5. Italy
10.2.1.6. Rest of Western Europe
10.2.2. By Drug Class
10.2.3. By Distribution Channel
10.3. Market Attractiveness Analysis
10.3.1. By Country
10.3.2. By Drug Class
10.3.3. By Distribution Channel
10.4. Key Takeaways
11. Eastern Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
11.2.1. By Country
11.2.1.1. Poland
11.2.1.2. Russia
11.2.1.3. Czech Republic
11.2.1.4. Romania
11.2.1.5. Rest of Eastern Europe
11.2.2. By Drug Class
11.2.3. By Distribution Channel
11.3. Market Attractiveness Analysis
11.3.1. By Country
11.3.2. By Drug Class
11.3.3. By Distribution Channel
11.4. Key Takeaways
12. South Asia and Pacific Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
12.2.1. By Country
12.2.1.1. India
12.2.1.2. Bangladesh
12.2.1.3. Australia
12.2.1.4. New Zealand
12.2.1.5. Rest of South Asia and Pacific
12.2.2. By Drug Class
12.2.3. By Distribution Channel
12.3. Market Attractiveness Analysis
12.3.1. By Country
12.3.2. By Drug Class
12.3.3. By Distribution Channel
12.4. Key Takeaways
13. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
13.2.1. By Country
13.2.1.1. China
13.2.1.2. Japan
13.2.1.3. South Korea
13.2.2. By Drug Class
13.2.3. By Distribution Channel
13.3. Market Attractiveness Analysis
13.3.1. By Country
13.3.2. By Drug Class
13.3.3. By Distribution Channel
13.4. Key Takeaways
14. Middle East and Africa Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
14.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
14.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
14.2.1. By Country
14.2.1.1. GCC Countries
14.2.1.2. South Africa
14.2.1.3. Israel
14.2.1.4. Rest of MEA
14.2.2. By Drug Class
14.2.3. By Distribution Channel
14.3. Market Attractiveness Analysis
14.3.1. By Country
14.3.2. By Drug Class
14.3.3. By Distribution Channel
14.4. Key Takeaways
15. Key Countries Market Analysis
15.1. USA
15.1.1. Pricing Analysis
15.1.2. Market Share Analysis, 2022
15.1.2.1. By Drug Class
15.1.2.2. By Distribution Channel
15.2. Canada
15.2.1. Pricing Analysis
15.2.2. Market Share Analysis, 2022
15.2.2.1. By Drug Class
15.2.2.2. By Distribution Channel
15.3. Brazil
15.3.1. Pricing Analysis
15.3.2. Market Share Analysis, 2022
15.3.2.1. By Drug Class
15.3.2.2. By Distribution Channel
15.4. Mexico
15.4.1. Pricing Analysis
15.4.2. Market Share Analysis, 2022
15.4.2.1. By Drug Class
15.4.2.2. By Distribution Channel
15.5. Germany
15.5.1. Pricing Analysis
15.5.2. Market Share Analysis, 2022
15.5.2.1. By Drug Class
15.5.2.2. By Distribution Channel
15.6. UK
15.6.1. Pricing Analysis
15.6.2. Market Share Analysis, 2022
15.6.2.1. By Drug Class
15.6.2.2. By Distribution Channel
15.7. France
15.7.1. Pricing Analysis
15.7.2. Market Share Analysis, 2022
15.7.2.1. By Drug Class
15.7.2.2. By Distribution Channel
15.8. Spain
15.8.1. Pricing Analysis
15.8.2. Market Share Analysis, 2022
15.8.2.1. By Drug Class
15.8.2.2. By Distribution Channel
15.9. Italy
15.9.1. Pricing Analysis
15.9.2. Market Share Analysis, 2022
15.9.2.1. By Drug Class
15.9.2.2. By Distribution Channel
15.10. Poland
15.10.1. Pricing Analysis
15.10.2. Market Share Analysis, 2022
15.10.2.1. By Drug Class
15.10.2.2. By Distribution Channel
15.11. Russia
15.11.1. Pricing Analysis
15.11.2. Market Share Analysis, 2022
15.11.2.1. By Drug Class
15.11.2.2. By Distribution Channel
15.12. Czech Republic
15.12.1. Pricing Analysis
15.12.2. Market Share Analysis, 2022
15.12.2.1. By Drug Class
15.12.2.2. By Distribution Channel
15.13. Romania
15.13.1. Pricing Analysis
15.13.2. Market Share Analysis, 2022
15.13.2.1. By Drug Class
15.13.2.2. By Distribution Channel
15.14. India
15.14.1. Pricing Analysis
15.14.2. Market Share Analysis, 2022
15.14.2.1. By Drug Class
15.14.2.2. By Distribution Channel
15.15. Bangladesh
15.15.1. Pricing Analysis
15.15.2. Market Share Analysis, 2022
15.15.2.1. By Drug Class
15.15.2.2. By Distribution Channel
15.16. Australia
15.16.1. Pricing Analysis
15.16.2. Market Share Analysis, 2022
15.16.2.1. By Drug Class
15.16.2.2. By Distribution Channel
15.17. New Zealand
15.17.1. Pricing Analysis
15.17.2. Market Share Analysis, 2022
15.17.2.1. By Drug Class
15.17.2.2. By Distribution Channel
15.18. China
15.18.1. Pricing Analysis
15.18.2. Market Share Analysis, 2022
15.18.2.1. By Drug Class
15.18.2.2. By Distribution Channel
15.19. Japan
15.19.1. Pricing Analysis
15.19.2. Market Share Analysis, 2022
15.19.2.1. By Drug Class
15.19.2.2. By Distribution Channel
15.20. South Korea
15.20.1. Pricing Analysis
15.20.2. Market Share Analysis, 2022
15.20.2.1. By Drug Class
15.20.2.2. By Distribution Channel
15.21. GCC Countries
15.21.1. Pricing Analysis
15.21.2. Market Share Analysis, 2022
15.21.2.1. By Drug Class
15.21.2.2. By Distribution Channel
15.22. South Africa
15.22.1. Pricing Analysis
15.22.2. Market Share Analysis, 2022
15.22.2.1. By Drug Class
15.22.2.2. By Distribution Channel
15.23. Israel
15.23.1. Pricing Analysis
15.23.2. Market Share Analysis, 2022
15.23.2.1. By Drug Class
15.23.2.2. By Distribution Channel
16. Market Structure Analysis
16.1. Competition Dashboard
16.2. Competition Benchmarking
16.3. Market Share Analysis of Top Players
16.3.1. By Regional
16.3.2. By Drug Class
16.3.3. By Distribution Channel
17. Competition Analysis
17.1. Competition Deep Dive
17.1.1. Interver Inc
17.1.1.1. Overview
17.1.1.2. Product Portfolio
17.1.1.3. Profitability by Market Segments
17.1.1.4. Sales Footprint
17.1.1.5. Strategy Overview
17.1.1.5.1. Marketing Strategy
17.1.2. Merck Animal Health
17.1.2.1. Overview
17.1.2.2. Product Portfolio
17.1.2.3. Profitability by Market Segments
17.1.2.4. Sales Footprint
17.1.2.5. Strategy Overview
17.1.2.5.1. Marketing Strategy
17.1.3. al Health
17.1.3.1. Overview
17.1.3.2. Product Portfolio
17.1.3.3. Profitability by Market Segments
17.1.3.4. Sales Footprint
17.1.3.5. Strategy Overview
17.1.3.5.1. Marketing Strategy
17.1.4. GlaxoSmithKline Plc.
17.1.4.1. Overview
17.1.4.2. Product Portfolio
17.1.4.3. Profitability by Market Segments
17.1.4.4. Sales Footprint
17.1.4.5. Strategy Overview
17.1.4.5.1. Marketing Strategy
17.1.5. Novartis AG
17.1.5.1. Overview
17.1.5.2. Product Portfolio
17.1.5.3. Profitability by Market Segments
17.1.5.4. Sales Footprint
17.1.5.5. Strategy Overview
17.1.5.5.1. Marketing Strategy
17.1.6. Bristol-Myers Squibb Company
17.1.6.1. Overview
17.1.6.2. Product Portfolio
17.1.6.3. Profitability by Market Segments
17.1.6.4. Sales Footprint
17.1.6.5. Strategy Overview
17.1.6.5.1. Marketing Strategy
17.1.7. Eli Lilly and Company
17.1.7.1. Overview
17.1.7.2. Product Portfolio
17.1.7.3. Profitability by Market Segments
17.1.7.4. Sales Footprint
17.1.7.5. Strategy Overview
17.1.7.5.1. Marketing Strategy
17.1.8. Pfizer Inc.
17.1.8.1. Overview
17.1.8.2. Product Portfolio
17.1.8.3. Profitability by Market Segments
17.1.8.4. Sales Footprint
17.1.8.5. Strategy Overview
17.1.8.5.1. Marketing Strategy
17.1.9. Boehringer Ingelheim International GmbH
17.1.9.1. Overview
17.1.9.2. Product Portfolio
17.1.9.3. Profitability by Market Segments
17.1.9.4. Sales Footprint
17.1.9.5. Strategy Overview
17.1.9.5.1. Marketing Strategy
17.1.10. Sanofi
17.1.10.1. Overview
17.1.10.2. Product Portfolio
17.1.10.3. Profitability by Market Segments
17.1.10.4. Sales Footprint
17.1.10.5. Strategy Overview
17.1.10.5.1. Marketing Strategy
17.1.11. Abbott Laboratories
17.1.11.1. Overview
17.1.11.2. Product Portfolio
17.1.11.3. Profitability by Market Segments
17.1.11.4. Sales Footprint
17.1.11.5. Strategy Overview
17.1.11.5.1. Marketing Strategy
17.1.12. F. Hoffmann-La Roche Ltd.
17.1.12.1. Overview
17.1.12.2. Product Portfolio
17.1.12.3. Profitability by Market Segments
17.1.12.4. Sales Footprint
17.1.12.5. Strategy Overview
17.1.12.5.1. Marketing Strategy
18. Assumptions & Acronyms Used19. Research Methodology
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
List of Tables
Table 1: Global Market Value (US$ Million) Forecast by Region, 2018 to 2033
Table 2: Global Market Value (US$ Million) Forecast by Drug Class, 2018 to 2033
Table 3: Global Market Value (US$ Million) Forecast by Distribution Channel, 2018 to 2033
Table 4: North America Market Value (US$ Million) Forecast by Country, 2018 to 2033
Table 5: North America Market Value (US$ Million) Forecast by Drug Class, 2018 to 2033
Table 6: North America Market Value (US$ Million) Forecast by Distribution Channel, 2018 to 2033
Table 7: Latin America Market Value (US$ Million) Forecast by Country, 2018 to 2033
Table 8: Latin America Market Value (US$ Million) Forecast by Drug Class, 2018 to 2033
Table 9: Latin America Market Value (US$ Million) Forecast by Distribution Channel, 2018 to 2033
Table 10: Western Europe Market Value (US$ Million) Forecast by Country, 2018 to 2033
Table 11: Western Europe Market Value (US$ Million) Forecast by Drug Class, 2018 to 2033
Table 12: Western Europe Market Value (US$ Million) Forecast by Distribution Channel, 2018 to 2033
Table 13: Eastern Europe Market Value (US$ Million) Forecast by Country, 2018 to 2033
Table 14: Eastern Europe Market Value (US$ Million) Forecast by Drug Class, 2018 to 2033
Table 15: Eastern Europe Market Value (US$ Million) Forecast by Distribution Channel, 2018 to 2033
Table 16: South Asia and Pacific Market Value (US$ Million) Forecast by Country, 2018 to 2033
Table 17: South Asia and Pacific Market Value (US$ Million) Forecast by Drug Class, 2018 to 2033
Table 18: South Asia and Pacific Market Value (US$ Million) Forecast by Distribution Channel, 2018 to 2033
Table 19: East Asia Market Value (US$ Million) Forecast by Country, 2018 to 2033
Table 20: East Asia Market Value (US$ Million) Forecast by Drug Class, 2018 to 2033
Table 21: East Asia Market Value (US$ Million) Forecast by Distribution Channel, 2018 to 2033
Table 22: Middle East and Africa Market Value (US$ Million) Forecast by Country, 2018 to 2033
Table 23: Middle East and Africa Market Value (US$ Million) Forecast by Drug Class, 2018 to 2033
Table 24: Middle East and Africa Market Value (US$ Million) Forecast by Distribution Channel, 2018 to 2033
Find your sweet spots for generating winning opportunities in this market.
List of Charts
Figure 1: Global Market Value (US$ Million) by Drug Class, 2023 to 2033
Figure 2: Global Market Value (US$ Million) by Distribution Channel, 2023 to 2033
Figure 3: Global Market Value (US$ Million) by Region, 2023 to 2033
Figure 4: Global Market Value (US$ Million) Analysis by Region, 2018 to 2033
Figure 5: Global Market Value Share (%) and BPS Analysis by Region, 2023 to 2033
Figure 6: Global Market Y-o-Y Growth (%) Projections by Region, 2023 to 2033
Figure 7: Global Market Value (US$ Million) Analysis by Drug Class, 2018 to 2033
Figure 8: Global Market Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033
Figure 9: Global Market Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033
Figure 10: Global Market Value (US$ Million) Analysis by Distribution Channel, 2018 to 2033
Figure 11: Global Market Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033
Figure 12: Global Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033
Figure 13: Global Market Attractiveness by Drug Class, 2023 to 2033
Figure 14: Global Market Attractiveness by Distribution Channel, 2023 to 2033
Figure 15: Global Market Attractiveness by Region, 2023 to 2033
Figure 16: North America Market Value (US$ Million) by Drug Class, 2023 to 2033
Figure 17: North America Market Value (US$ Million) by Distribution Channel, 2023 to 2033
Figure 18: North America Market Value (US$ Million) by Country, 2023 to 2033
Figure 19: North America Market Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 20: North America Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 21: North America Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 22: North America Market Value (US$ Million) Analysis by Drug Class, 2018 to 2033
Figure 23: North America Market Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033
Figure 24: North America Market Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033
Figure 25: North America Market Value (US$ Million) Analysis by Distribution Channel, 2018 to 2033
Figure 26: North America Market Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033
Figure 27: North America Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033
Figure 28: North America Market Attractiveness by Drug Class, 2023 to 2033
Figure 29: North America Market Attractiveness by Distribution Channel, 2023 to 2033
Figure 30: North America Market Attractiveness by Country, 2023 to 2033
Figure 31: Latin America Market Value (US$ Million) by Drug Class, 2023 to 2033
Figure 32: Latin America Market Value (US$ Million) by Distribution Channel, 2023 to 2033
Figure 33: Latin America Market Value (US$ Million) by Country, 2023 to 2033
Figure 34: Latin America Market Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 35: Latin America Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 36: Latin America Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 37: Latin America Market Value (US$ Million) Analysis by Drug Class, 2018 to 2033
Figure 38: Latin America Market Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033
Figure 39: Latin America Market Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033
Figure 40: Latin America Market Value (US$ Million) Analysis by Distribution Channel, 2018 to 2033
Figure 41: Latin America Market Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033
Figure 42: Latin America Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033
Figure 43: Latin America Market Attractiveness by Drug Class, 2023 to 2033
Figure 44: Latin America Market Attractiveness by Distribution Channel, 2023 to 2033
Figure 45: Latin America Market Attractiveness by Country, 2023 to 2033
Figure 46: Western Europe Market Value (US$ Million) by Drug Class, 2023 to 2033
Figure 47: Western Europe Market Value (US$ Million) by Distribution Channel, 2023 to 2033
Figure 48: Western Europe Market Value (US$ Million) by Country, 2023 to 2033
Figure 49: Western Europe Market Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 50: Western Europe Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 51: Western Europe Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 52: Western Europe Market Value (US$ Million) Analysis by Drug Class, 2018 to 2033
Figure 53: Western Europe Market Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033
Figure 54: Western Europe Market Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033
Figure 55: Western Europe Market Value (US$ Million) Analysis by Distribution Channel, 2018 to 2033
Figure 56: Western Europe Market Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033
Figure 57: Western Europe Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033
Figure 58: Western Europe Market Attractiveness by Drug Class, 2023 to 2033
Figure 59: Western Europe Market Attractiveness by Distribution Channel, 2023 to 2033
Figure 60: Western Europe Market Attractiveness by Country, 2023 to 2033
Figure 61: Eastern Europe Market Value (US$ Million) by Drug Class, 2023 to 2033
Figure 62: Eastern Europe Market Value (US$ Million) by Distribution Channel, 2023 to 2033
Figure 63: Eastern Europe Market Value (US$ Million) by Country, 2023 to 2033
Figure 64: Eastern Europe Market Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 65: Eastern Europe Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 66: Eastern Europe Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 67: Eastern Europe Market Value (US$ Million) Analysis by Drug Class, 2018 to 2033
Figure 68: Eastern Europe Market Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033
Figure 69: Eastern Europe Market Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033
Figure 70: Eastern Europe Market Value (US$ Million) Analysis by Distribution Channel, 2018 to 2033
Figure 71: Eastern Europe Market Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033
Figure 72: Eastern Europe Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033
Figure 73: Eastern Europe Market Attractiveness by Drug Class, 2023 to 2033
Figure 74: Eastern Europe Market Attractiveness by Distribution Channel, 2023 to 2033
Figure 75: Eastern Europe Market Attractiveness by Country, 2023 to 2033
Figure 76: South Asia and Pacific Market Value (US$ Million) by Drug Class, 2023 to 2033
Figure 77: South Asia and Pacific Market Value (US$ Million) by Distribution Channel, 2023 to 2033
Figure 78: South Asia and Pacific Market Value (US$ Million) by Country, 2023 to 2033
Figure 79: South Asia and Pacific Market Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 80: South Asia and Pacific Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 81: South Asia and Pacific Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 82: South Asia and Pacific Market Value (US$ Million) Analysis by Drug Class, 2018 to 2033
Figure 83: South Asia and Pacific Market Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033
Figure 84: South Asia and Pacific Market Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033
Figure 85: South Asia and Pacific Market Value (US$ Million) Analysis by Distribution Channel, 2018 to 2033
Figure 86: South Asia and Pacific Market Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033
Figure 87: South Asia and Pacific Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033
Figure 88: South Asia and Pacific Market Attractiveness by Drug Class, 2023 to 2033
Figure 89: South Asia and Pacific Market Attractiveness by Distribution Channel, 2023 to 2033
Figure 90: South Asia and Pacific Market Attractiveness by Country, 2023 to 2033
Figure 91: East Asia Market Value (US$ Million) by Drug Class, 2023 to 2033
Figure 92: East Asia Market Value (US$ Million) by Distribution Channel, 2023 to 2033
Figure 93: East Asia Market Value (US$ Million) by Country, 2023 to 2033
Figure 94: East Asia Market Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 95: East Asia Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 96: East Asia Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 97: East Asia Market Value (US$ Million) Analysis by Drug Class, 2018 to 2033
Figure 98: East Asia Market Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033
Figure 99: East Asia Market Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033
Figure 100: East Asia Market Value (US$ Million) Analysis by Distribution Channel, 2018 to 2033
Figure 101: East Asia Market Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033
Figure 102: East Asia Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033
Figure 103: East Asia Market Attractiveness by Drug Class, 2023 to 2033
Figure 104: East Asia Market Attractiveness by Distribution Channel, 2023 to 2033
Figure 105: East Asia Market Attractiveness by Country, 2023 to 2033
Figure 106: Middle East and Africa Market Value (US$ Million) by Drug Class, 2023 to 2033
Figure 107: Middle East and Africa Market Value (US$ Million) by Distribution Channel, 2023 to 2033
Figure 108: Middle East and Africa Market Value (US$ Million) by Country, 2023 to 2033
Figure 109: Middle East and Africa Market Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 110: Middle East and Africa Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 111: Middle East and Africa Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 112: Middle East and Africa Market Value (US$ Million) Analysis by Drug Class, 2018 to 2033
Figure 113: Middle East and Africa Market Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033
Figure 114: Middle East and Africa Market Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033
Figure 115: Middle East and Africa Market Value (US$ Million) Analysis by Distribution Channel, 2018 to 2033
Figure 116: Middle East and Africa Market Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033
Figure 117: Middle East and Africa Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033
Figure 118: Middle East and Africa Market Attractiveness by Drug Class, 2023 to 2033
Figure 119: Middle East and Africa Market Attractiveness by Distribution Channel, 2023 to 2033
Figure 120: Middle East and Africa Market Attractiveness by Country, 2023 to 2033
